Rokaya El Ansari

1.3k total citations
24 papers, 891 citations indexed

About

Rokaya El Ansari is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Rokaya El Ansari has authored 24 papers receiving a total of 891 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 15 papers in Cancer Research and 12 papers in Oncology. Recurrent topics in Rokaya El Ansari's work include Cancer, Hypoxia, and Metabolism (12 papers), Amino Acid Enzymes and Metabolism (10 papers) and Epigenetics and DNA Methylation (10 papers). Rokaya El Ansari is often cited by papers focused on Cancer, Hypoxia, and Metabolism (12 papers), Amino Acid Enzymes and Metabolism (10 papers) and Epigenetics and DNA Methylation (10 papers). Rokaya El Ansari collaborates with scholars based in United Kingdom, United States and Saudi Arabia. Rokaya El Ansari's co-authors include Emad A. Rakha, Andrew R. Green, Madeleine L. Craze, Ian O. Ellis, Lutfi Alfarsi, Brendah K. Masisi, Maria Diez‐Rodriguez, Christopher C. Nolan, Mohammed A. Aleskandarany and Michael S. Toss and has published in prestigious journals such as Cancer Research, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Rokaya El Ansari

24 papers receiving 885 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rokaya El Ansari United Kingdom	18	629	475	212	192	134	24	891
Madeleine L. Craze United Kingdom	18	638 1.0×	451 0.9×	204 1.0×	188 1.0×	127 0.9×	22	892
Megan D. Hoeksema United States	13	794 1.3×	552 1.2×	210 1.0×	215 1.1×	278 2.1×	13	1.2k
Bradford K. Harris United States	9	628 1.0×	492 1.0×	175 0.8×	210 1.1×	230 1.7×	10	958
Gina N. Alesi United States	7	612 1.0×	474 1.0×	148 0.7×	53 0.3×	124 0.9×	9	898
Sminu Bose United States	6	849 1.3×	748 1.6×	179 0.8×	88 0.5×	103 0.8×	14	1.2k
Mirna L.M. Rodriguez United States	9	781 1.2×	756 1.6×	211 1.0×	166 0.9×	134 1.0×	16	1.1k
Lou Baudrier United States	7	642 1.0×	503 1.1×	111 0.5×	81 0.4×	172 1.3×	10	890
Thai Q. Tran United States	14	732 1.2×	646 1.4×	247 1.2×	91 0.5×	61 0.5×	18	1.1k
Florian Röhrig Germany	5	830 1.3×	905 1.9×	164 0.8×	140 0.7×	180 1.3×	6	1.3k
Ibtissam Marchiq France	12	939 1.5×	756 1.6×	198 0.9×	89 0.5×	108 0.8×	16	1.3k

Countries citing papers authored by Rokaya El Ansari

Since Specialization

Citations

This map shows the geographic impact of Rokaya El Ansari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rokaya El Ansari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rokaya El Ansari more than expected).

Fields of papers citing papers by Rokaya El Ansari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rokaya El Ansari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rokaya El Ansari. The network helps show where Rokaya El Ansari may publish in the future.

Co-authorship network of co-authors of Rokaya El Ansari

This figure shows the co-authorship network connecting the top 25 collaborators of Rokaya El Ansari. A scholar is included among the top collaborators of Rokaya El Ansari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rokaya El Ansari. Rokaya El Ansari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alfarsi, Lutfi, et al.. (2025). SLC1A5 is a key regulator of glutamine metabolism and a prognostic marker for aggressive luminal breast cancer. Scientific Reports. 15(1). 2805–2805. 3 indexed citations

Masisi, Brendah K., Rokaya El Ansari, Lutfi Alfarsi, et al.. (2024). Tripartite Motif-Containing 2, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Triple-Negative Breast Cancer Treated with Chemotherapy. Cancers. 16(11). 1949–1949. 1 indexed citations

Alfarsi, Lutfi, Rokaya El Ansari, Brendah K. Masisi, et al.. (2024). ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Oestrogen Receptor-Positive Breast Cancer. Pathobiology. 91(6). 411–421. 3 indexed citations

Masisi, Brendah K., Rokaya El Ansari, Lutfi Alfarsi, et al.. (2021). The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer. Cancers. 13(16). 3963–3963. 17 indexed citations

Ansari, Rokaya El, Lutfi Alfarsi, Madeleine L. Craze, et al.. (2020). The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment. 181(1). 1–12. 14 indexed citations

Alfarsi, Lutfi, Rokaya El Ansari, Madeleine L. Craze, et al.. (2020). Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences. 21(4). 1407–1407. 32 indexed citations

Alfarsi, Lutfi, Rokaya El Ansari, Madeleine L. Craze, et al.. (2020). PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer. 20(1). 425–425. 13 indexed citations

Alfarsi, Lutfi, Rokaya El Ansari, Brendah K. Masisi, et al.. (2020). Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. Cancers. 12(6). 1549–1549. 7 indexed citations

Morotti, Matteo, Christos E. Zois, Rokaya El Ansari, et al.. (2020). Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. British Journal of Cancer. 124(2). 494–505. 88 indexed citations

10.

Ansari, Rokaya El, Madeleine L. Craze, Lutfi Alfarsi, et al.. (2019). The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer. Breast Cancer Research and Treatment. 175(1). 27–38. 26 indexed citations

11.

Toss, Michael S., Sasagu Kurozumi, Chitra Joseph, et al.. (2019). The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer. Breast Cancer Research and Treatment. 179(1). 79–90. 19 indexed citations

12.

Ansari, Rokaya El, Madeleine L. Craze, Maryam Althobiti, et al.. (2019). Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer. British Journal of Cancer. 122(1). 94–101. 44 indexed citations

13.

Alfarsi, Lutfi, Rokaya El Ansari, Madeleine L. Craze, et al.. (2019). CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Research and Treatment. 178(3). 535–544. 34 indexed citations

14.

Ansari, Rokaya El, Madeleine L. Craze, Islam M. Miligy, et al.. (2018). The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours. Breast Cancer Research. 20(1). 21–21. 105 indexed citations

15.

Luan, Haitao, Bhopal Mohapatra, Insha Mushtaq, et al.. (2018). Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program. Cancer Research. 78(10). 2524–2535. 36 indexed citations

16.

Ansari, Rokaya El, Madeleine L. Craze, Maria Diez‐Rodriguez, et al.. (2018). The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. British Journal of Cancer. 118(8). 1115–1122. 47 indexed citations

17.

Craze, Madeleine L., Rokaya El Ansari, Mohammed A. Aleskandarany, et al.. (2018). Glutamate dehydrogenase (GLUD1) expression in breast cancer. Breast Cancer Research and Treatment. 174(1). 79–91. 38 indexed citations

18.

Alfarsi, Lutfi, Rokaya El Ansari, Michael S. Toss, et al.. (2018). Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer. Breast Cancer Research and Treatment. 173(1). 93–102. 25 indexed citations

19.

Craze, Madeleine L., Daniele Soria, Rokaya El Ansari, et al.. (2017). MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer. British Journal of Cancer. 118(2). 258–265. 75 indexed citations

20.

Ansari, Rokaya El, Alan McIntyre, Madeleine L. Craze, et al.. (2017). Altered glutamine metabolism in breast cancer; subtype dependencies and alternative adaptations. Histopathology. 72(2). 183–190. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact